32 Biosciences Secures $6 Million Funding to Advance Gut Microbiome Diagnostic and Therapeutic Platform
32 Biosciences raised $6 million in funding to advance its AI-powered gut microbiome diagnostic platform and first-of-its-kind non-antibiotic antimicrobial therapy.
New Study Raises Safety Concerns About Fecal Microbiota Transplants
A new study published June 6, 2025, warns that fecal microbiota transplants may introduce microbes that hijack the host environment, potentially creating new health risks.
AB Science Secures Chinese Patent for Masitinib in COVID-19 Treatment Until 2041
AB Science has received a Chinese patent for its lead compound masitinib to treat COVID-19, providing intellectual property protection until April 2041.
ClostraBio Secures INVENT Illinois Funding, Appoints New CSO, and Prepares for Microbiome Therapeutic Launch
ClostraBio has secured new investment from the Illinois Innovation Venture Fund (INVENT) and NextGen Nutrition Investment Partners to advance its microbiome-focused therapeutics for gut health.
Weight Loss Drugs Wegovy and Zepbound Not Cost-Effective at Current Prices, Study Finds
Popular weight loss medications semaglutide (Wegovy) and tirzepatide (Zepbound) would need significant price reductions of 82% and 30% respectively to meet standard cost-effectiveness thresholds, according to new University of Chicago research.
Climate Change Extends Pollen Seasons, Prompting New Approaches to Allergy Management
Climate change has significantly extended pollen seasons across the United States, with western regions experiencing up to 20 additional freeze-free days, leading to prolonged allergy symptoms.
Radiation Oncology Pioneer Ralph Weichselbaum Named 2024 Giants of Cancer Care Inductee
Dr. Ralph R. Weichselbaum, chair of Radiation and Cellular Oncology at University of Chicago, has been named the 2024 Giants of Cancer Care inductee for his groundbreaking contributions to radiation oncology.
Dato-DXd Shows Promise in Previously Treated Advanced Non-Small Cell Lung Cancer
Datopotamab deruxtecan (Dato-DXd) showed a numerical improvement in overall survival compared to docetaxel in previously treated advanced non-small cell lung cancer (NSCLC).
Vertex's VX-880 Stem Cell Therapy Achieves Insulin Independence in Type 1 Diabetes Patients
Vertex Pharmaceuticals' VX-880 stem cell-derived islet cell therapy demonstrated remarkable efficacy in a Phase I/II trial, with all 12 full-dose patients achieving improved glycemic control and meeting ADA targets for HbA1c and time-in-range.
FDA-Approved Cancer Drug Ruxolitinib Shows Promise for Treating Cardiac Arrhythmias
Researchers from Johns Hopkins University and University of Chicago discovered that ruxolitinib, an FDA-approved cancer and skin condition drug, effectively inhibits CaMKII protein kinase linked to cardiac arrhythmias.